As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...

Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice SOC was dominated by ...

Several new treatment combinations have been approved in metastatic renal cell carcinoma (mRCC). To determine the optimal therapy on the basis of cost and health outcomes, we performed a ...

The Food and Drug Administration recently approved betibeglogene autotemcel (Zynteglo), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who ...

Demand for humanitarian assistance is growing and existing financial resources are inadequate to address all areas of need. As stewards of limited funds, we have a responsibility to make the most ...

This systematic review found that studies of case management interventions have adequate quality and, in many cases, show cost-effective or even cost-saving results. Results: A total of 29 studies ...

Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine. Objective: Migraine is a debilitating chronic disorder requiring multifaceted ...

Data sources Medline, Embase, Web of Science, Scopus, National Institute for Health Research Economic Evaluation Database, Health Technology Assessment database, Tufts Cost-Effectiveness Analysis ...

Investigators analyzed economic evaluations of adjuvant immunotherapy to assess cost-effectiveness outcomes, quality-adjusted life-year (QALY)/life-year (LY) gains, and methodologic approaches.

Most importantly, the practice of benefit-cost analysis has been reinforced by decades of bipartisan presidential agreement, ...